Letter: lipid-lowering effect of tenofovir disoproxil fumarate in chronic hepatitis B-more evidence is needed. Authors' reply

Affiliations

Comment

A A Shaheen et al. Aliment Pharmacol Ther. 2017 Oct.

. 2017 Oct;46(8):770-771.

doi: 10.1111/apt.14282.

¹ Calgary Liver Unit, Division of Gastroenterology and Hepatology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

No abstract available

Comment on

Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos(t)ide analogue therapy in chronic hepatitis B carriers.
Shaheen AA, AlMattooq M, Yazdanfar S, Burak KW, Swain MG, Congly SE, Borman MA, Lee SS, Myers RP, Coffin CS. Shaheen AA, et al. Aliment Pharmacol Ther. 2017 Sep;46(6):599-604. doi: 10.1111/apt.14218. Epub 2017 Jul 13. Aliment Pharmacol Ther. 2017. PMID: 28707319
Letter: lipid-lowering effect of tenofovir disoproxil fumarate in chronic hepatitis B-more evidence is needed.
Huang R, Wang J, Xia J, Yan X, Wu C. Huang R, et al. Aliment Pharmacol Ther. 2017 Oct;46(8):769-770. doi: 10.1111/apt.14266. Aliment Pharmacol Ther. 2017. PMID: 28901572 No abstract available.